drugset / Trial / NCT04630756
AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a modular, multicentre, open-label, non-randomised, Phase I/II, dose-setting and expansion study including an intra-participants dose ramp up. AZD4573 will be administered intravenously, in novel combinations with anti-cancer agents, to participants with relapsed/refractory (r/r) haematological malignancies.
Timeline
- Start
- 2021-02-17
- Primary completion
- 2023-09-08
- Completion
- 2025-02-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acalabrutinib | Small molecule | 100 mg | Oral |
| Subject | ZEMIRCICLIB | Small molecule | 12 mg | Intravenous |